+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Proton pump inhibitors use in hemodialysis patients and serum magnesium levels



Proton pump inhibitors use in hemodialysis patients and serum magnesium levels



International Journal of Clinical and Experimental Medicine 8(11): 21689-21693



Hypomagnesemia is reported in patients who use proton pump inhibitors (PPIs). We investigated the effect of PPIs use on serum magnesium levels in hemodialysis patients. Our study was conducted in a hemodialysis center including 75 end stage renal disease patients. PPI use and duration were investigated. All patients were dialyzed using a dialysate magnesium level of 0.5-0.75 mmol/L. After at least one month of hemodialysis with the mentioned dialysate, laboratory tests were performed. Fifty-four patients (72%) used PPIs while 21 (28%) did not. The mean duration of PPI use was 42.5 ± 35 months. There was no significant difference between serum magnesium levels of patients who used and did not use PPIs (2.73 ± 0.3 vs. 2.88 ± 0.3 mg/dL, P = ns). There were 15 patients (20%) with a dialysate magnesium level of 0.5 mmol/l and 60 patients (80%) with a dialysate magnesium level of 0.75 mmol/L. The mean serum magnesium levels of patients with a dialysate magnesium level of 0.5 mmol/L was 2.45 ± 0.3 mg/dL while that of patients with a dialysate magnesium level of 0.75 mmol/L was 2.85 ± 0.3 mg/dL (P<0.0001). In hemodialysis patients, PPI use did not affect serum magnesium levels. The most important factor affecting the serum magnesium levels in hemodialysis patients is the dialysate magnesium concentration.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 058654659

Download citation: RISBibTeXText

PMID: 26885127


Related references

Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes. Frontiers in Pharmacology 9: 363, 2018

Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients. Journal of Nephrology 27(6): 707-711, 2016

The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study. Bmc Nephrology 16: 136, 2016

Magnesium and parathyroid hormone levels of patients using different proton pump inhibitors: is there a real link?. Gastroenterology Nursing 36(2): 145-148, 2014

Serum magnesium and proton-pump inhibitors use: a cross-sectional study. Revista Da Associacao Medica Brasileira 59(3): 276-279, 2014

Influence of proton pump inhibitors and histamine H 2 receptor antagonists on serum phosphorus level control by calcium carbonate in patients undergoing hemodialysis: a retrospective medical chart review. Journal of Pharmaceutical Health Care and Sciences 2: 34, 2016

Proton pump inhibitors are associated with lower magnesium levels in older people with chronic kidney disease. Journal of the American Geriatrics Society 60(2): 392-393, 2012

Proton Pump Inhibitor Use and Magnesium Concentrations in Hemodialysis Patients: A Cross-Sectional Study. Plos One 10(11): E0143656, 2016

Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors. American Journal of Nephrology 39(3): 204-209, 2014

Uses of proton pump inhibitors and serum potassium levels. Pharmacoepidemiology and Drug Safety 18(9): 865-871, 2009

Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics. Jgh Open 2(2): 47-53, 2018

Is there a relationship between hypomagnesemia and proton-pump inhibitors in patients on chronic hemodialysis?. European Journal of Internal Medicine 30: 99-103, 2017

Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study. Journal of Gastroenterology 2019, 2019

Inulin significantly improves serum magnesium levels in proton pump inhibitor-induced hypomagnesaemia. Alimentary Pharmacology and Therapeutics 43(11): 1178-1185, 2017

Increased Proton Pump Inhibitors-Induced Mortality Risk in Hemodialysis Patients. Kidney International Reports 4(3): 505, 2019